Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Julphar
US Department of Justice
Chinese Patent Office
Mallinckrodt
Colorcon
Citi
Boehringer Ingelheim
Cipla
Novartis

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 078654

« Back to Dashboard

NDA 078654 describes CLONAZEPAM, which is a drug marketed by Barr, Par Pharm, Sun Pharm Inds Inc, Accord Hlthcare, Actavis Elizabeth, Apotex Inc, Mylan, Mylan Pharms Inc, Prinston Inc, Sandoz, Teva, and Watson Labs, and is included in fifteen NDAs. It is available from forty-seven suppliers. Additional details are available on the CLONAZEPAM profile page.

The generic ingredient in CLONAZEPAM is clonazepam. There are ten drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the clonazepam profile page.
Summary for 078654
Tradename:CLONAZEPAM
Applicant:Sun Pharm Inds Inc
Ingredient:clonazepam
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 078654
Ingredient-typeBenzodiazepines
Medical Subject Heading (MeSH) Categories for 078654
Suppliers and Packaging for NDA: 078654
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLONAZEPAM clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 078654 ANDA Sun Pharmaceutical Industries, Inc. 57664-783 N 57664-783-88
CLONAZEPAM clonazepam TABLET, ORALLY DISINTEGRATING;ORAL 078654 ANDA Sun Pharmaceutical Industries, Inc. 57664-783 N 57664-783-86

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength0.125MG
Approval Date:Aug 27, 2014TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength0.25MG
Approval Date:Aug 27, 2014TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength0.5MG
Approval Date:Aug 27, 2014TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Federal Trade Commission
Harvard Business School
US Army
Cantor Fitzgerald
Healthtrust
Johnson and Johnson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot